Inside Latigo Biotherapeutics’ IPO: A Non

Latigo Biotherapeutics (NASDAQ:LTGO) priced its IPO at $18 and opened at $21, raising nearly $350 million. Shares later traded around $19.38. The clinical-stage company targets non-opioid pain via selective Nav1.8 inhibitors, including LTG-001, which met a Phase 2 abdominoplasty endpoint. Cash was $69.4M at Dec. 31, 2025, with going-concern language in its S-1.

Latigo Biotherapeutics, a Thousand Oaks biotech developing non-opioid pain medicines, IPOed Aug. 6. According to the company, it raised $345.6 million in an upsized offering, selling 19.2 million shares at $18 (vs. 16 million at $16-$18). Shares began trading on Nasdaq Aug. 7 as LTGO and closed at $18.25.

Latigo Biotherapeutics IPO raised $346M to fund its non-opioid pain pipeline, including LTG-001, a NaV1.8 blocker targeting Phase 3. In a Phase 2b abdominoplasty trial (343 patients), both doses reduced pain vs placebo; only the high dose cut opioid rescue use. Latigo says meaningful relief began in 52 minutes. Shares began trading on Nasdaq as LTGO.

Latigo Biotherapeutics (Nasdaq: LTGO) priced its IPO at $18 per share, raising $345.6 million, according to the IPO announcement. The company said the proceeds will fund its non-opioid painkiller program. Goldman Sachs, Jefferies, Leerink and Guggenheim served as bookrunners.

Latigo Biotherapeutics priced an upsized US$345.6 million IPO, selling 19.2 million shares at US$18 per share. All shares were offered by Latigo, with gross proceeds expected to be US$345.6 million before fees. Underwriters have a 30-day option to buy up to 2.88 million additional shares at the same price. Latham & Watkins represented the underwriters.

Latigo Biotherapeutics Inc. (NASDAQ:LTGO) shares rose 17% after an upsized IPO. The company raised $345.6 million by selling 19.2 million shares at $18, the top of its $16 to $18 range. It priced above the marketed size, opened at $21, and has a 30-day option for 2.88 million more shares.